Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

ABBV

AbbVie (ABBV)

AbbVie Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:ABBV
DateTimeSourceHeadlineSymbolCompany
04/01/20215:10PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
04/01/20215:10PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
04/01/20215:10PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
04/01/20218:45AMPR Newswire (US)SkinMedica® Launches Neck Correct Cream for Neck and DécolletéNYSE:ABBVAbbVie Inc
04/01/20218:31AMPR Newswire (US)New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic...NYSE:ABBVAbbVie Inc
03/31/20212:19PMEdgar (US Regulatory)Notice of Exempt Solicitation. Definitive Material. (px14a6g)NYSE:ABBVAbbVie Inc
03/31/20218:00AMPR Newswire (US)AbbVie to Host First-Quarter 2021 Earnings Conference CallNYSE:ABBVAbbVie Inc
03/30/20218:50AMDow Jones NewsAbbVie: FDA to Review Atogepant for Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
03/30/20218:00AMPR Newswire (US)U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
03/29/202110:57AMEdgar (US Regulatory)Notice of Exempt Solicitation. Definitive Material. (px14a6g)NYSE:ABBVAbbVie Inc
03/24/20218:45AMInvestorWireControlling Inflammation to Stop DiseaseNYSE:ABBVAbbVie Inc
03/22/20215:03PMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NYSE:ABBVAbbVie Inc
03/22/20215:01PMEdgar (US Regulatory)Proxy Statement (definitive) (def 14a)NYSE:ABBVAbbVie Inc
03/17/202112:01PMDow Jones NewsAbbVie Down Over 6%, On Pace for Largest Percent Decrease Since March 2020 -- Data TalkNYSE:ABBVAbbVie Inc
03/17/20219:50AMDow Jones NewsAbbVie: FDA Seeks More Data, Extends Rinvoq ReviewNYSE:ABBVAbbVie Inc
03/17/20218:45AMPR Newswire (US)AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Adults with A...NYSE:ABBVAbbVie Inc
03/12/20215:03PMEdgar (US Regulatory)Current Report Filing (8-k)NYSE:ABBVAbbVie Inc
03/08/20215:28PMEdgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NYSE:ABBVAbbVie Inc
03/07/20215:59AMDow Jones NewsHaving Trouble Getting the Covid Vaccine? Your Company Might Soon Offer It.NYSE:ABBVAbbVie Inc
02/26/20211:58PMDow Jones NewsWarren Buffett's Annual Letter Is About to LandNYSE:ABBVAbbVie Inc
02/25/20218:58AMDow Jones NewsAbbVie's Allergan Seeks FDA OK of AGN-190584 in PresbyopiaNYSE:ABBVAbbVie Inc
02/25/20218:00AMPR Newswire (US)Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of PresbyopiaNYSE:ABBVAbbVie Inc
02/24/20217:14PMPR Newswire (US)HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative ...NYSE:ABBVAbbVie Inc
02/24/20216:29PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
02/24/202112:02PMDow Jones NewsAbbVie: Skyrizi to Treat Psoriasis Gets Public Payer Coverage in PEINYSE:ABBVAbbVie Inc
02/24/202111:21AMPR Newswire (Canada)SKYRIZI®, commercialisé par AbbVie pour le traitement du psoriasis en plaques modéré à grave, est désormais remboursé ...NYSE:ABBVAbbVie Inc
02/24/202111:09AMPR Newswire (Canada)AbbVie's SKYRIZI® for the Treatment of Moderate to Severe Plaque Psoriasis now Publicly Reimbursed across CanadaNYSE:ABBVAbbVie Inc
02/23/20218:30AMPR Newswire (US)New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen UseNYSE:ABBVAbbVie Inc
02/22/20216:26PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
02/22/20216:25PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:ABBVAbbVie Inc
 Showing the most relevant articles for your search:NYSE:ABBV